Stonegate Capital Partners has released an updated research report on Incannex Healthcare Inc. (NasdaqGM:IXHL), focusing on the company's progress with IHL-42X for obstructive sleep apnea (OSA). The announcement follows full Phase 2 RePOSA data and exit-interview analyses, which showed statistically significant reductions in Apnea-Hypopnoea Index (AHI) for both low and high-dose IHL-42X compared to placebo. Maximum AHI reductions reached up to 83% in the high-dose arm, and exit interviews revealed that 57.6% of participants perceived improvement in their OSA, with most describing the change as meaningful to daily life. IHL-42X was well tolerated across both dose cohorts, reinforcing its potential for broad use.
In addition to the positive clinical data, Incannex reported cash and cash equivalents of $68.9 million, providing a strong financial foundation to advance its pipeline. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, which may expedite the development and review process. The company also reported positive Phase 2 results for PSX-001, another candidate in its portfolio. For more details, the full announcement is available at Stonegate's website.
This update from Stonegate Capital Partners underscores the significance of Incannex's clinical advancements and the potential impact on the OSA treatment landscape. With a strong cash position and regulatory support, Incannex is well-positioned to continue its development efforts. The company's focus on patient-reported outcomes and AHI reductions aligns with key metrics for OSA therapies, suggesting a promising path forward for IHL-42X.
